Crossmark

Modified hTERT promoters-driven purine nucleoside phosphorylase-gene therapy in association with chemo- and targeted therapy in the context of ovarian cancer

Crossref DOI link: https://doi.org/10.1038/s41417-025-00932-6

Published Online: 2025-06-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nguyen, Quoc Manh https://orcid.org/0000-0003-1997-0413
Dupré, Pierre-François

Berchel, Mathieu

Lévêque, Marylène

Choblet-Thery, Sylvie

d’Arbonneau, Frédérique

Montier, Tristan https://orcid.org/0000-0003-0452-6395
License Information

Text and Data Mining valid from 2025-06-27

Version of Record valid from 2025-06-27
More Information

Article History

Received: 10 February 2025

Revised: 27 May 2025

Accepted: 12 June 2025

First Online: 27 June 2025

Competing interests

: The authors declare no competing interests.

: The research complies with ethical principles and applicable international, EU, and French law, in particular, EU directives 2004/23/EC and 2010/63/EU. For in vitro experiments, fibroblasts were extracted from Human skin explants. They were obtained from abdominal reduction surgery after the donor gave their written informed consent. Sample collection was referenced under number DC-2014-2319. The study was approved by the local ethics committee Ouest VI and realized in accordance with European Law.

Document is current

Any future updates will be listed below